NASDAQ:SRDX Surmodics (SRDX) Stock Forecast, Price & News $31.70 -0.39 (-1.22%) (As of 09:35 AM ET) Add Compare Share Share Today's Range$30.99▼$31.7450-Day Range$31.10▼$38.3652-Week Range$16.00▼$39.41Volume3,972 shsAverage Volume117,315 shsMarket Capitalization$447.92 millionP/E RatioN/ADividend YieldN/APrice Target$59.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Surmodics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.7% Upside$59.50 Price TargetShort InterestHealthy0.91% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews Sentiment1.28Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.22) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector479th out of 969 stocksSurgical & Medical Instruments Industry57th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.50, Surmodics has a forecasted upside of 87.7% from its current price of $31.70.Amount of Analyst CoverageSurmodics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.91% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently increased by 1.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 2.9 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Surmodics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Surmodics is held by insiders.Percentage Held by Institutions87.09% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to decrease in the coming year, from ($0.22) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is -19.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is -19.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Surmodics (NASDAQ:SRDX) StockSurmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comSurmodics (NASDAQ:SRDX) Share Price Crosses Above 200 Day Moving Average of $27.22September 12, 2023 | finance.yahoo.comSurmodics (SRDX) Hits 52-Week High: What's Driving the Stock?October 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 6, 2023 | finance.yahoo.comWhy You Should Add Surmodics (SRDX) Stock to Your PortfolioAugust 9, 2023 | finance.yahoo.comSurmodics to Participate in Upcoming Investor Conferences in AugustAugust 3, 2023 | finance.yahoo.comSurmodics (SRDX) Q3 Earnings Top Estimates, FY23 View UpAugust 3, 2023 | msn.comNeedham Reiterates Surmodics (SRDX) Buy RecommendationAugust 2, 2023 | finance.yahoo.comSurmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial GuidanceOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 2, 2023 | finance.yahoo.comSurModics (SRDX) Surpasses Q3 Earnings and Revenue EstimatesAugust 2, 2023 | finance.yahoo.comSurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesJuly 12, 2023 | finance.yahoo.comSurmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2June 28, 2023 | finance.yahoo.comThree Reasons to Add Surmodics (SRDX) Stock to Your PortfolioJune 22, 2023 | msn.comSurmodics: Regulatory, Fundamental Catalysts Show 90% Upside PotentialJune 21, 2023 | bizjournals.comSurmodics stock jumps on FDA approval of SurVeil drug-coated balloonJune 21, 2023 | finance.yahoo.comStrength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?June 20, 2023 | msn.comDICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On TuesdayJune 20, 2023 | startribune.comEden Prairie's Surmodics receives key FDA approval, unlocking a $27M milestone paymentJune 20, 2023 | finance.yahoo.comAfter FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA ApprovalJune 20, 2023 | finance.yahoo.comSurmodics Receives FDA Approval for the SurVeil™ Drug-Coated BalloonJune 16, 2023 | finance.yahoo.comSurmodics' (SRDX) Receipt of New FDA Nod to Boost Patient CareJune 14, 2023 | finance.yahoo.comSurmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy SystemJune 13, 2023 | markets.businessinsider.comSecond Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB ApplicationJune 13, 2023 | msn.comNeedham Upgrades Surmodics (SRDX)June 4, 2023 | fool.comSurmodics (NASDAQ: SRDX)May 25, 2023 | finance.yahoo.comSurmodics to Participate in the Jefferies Healthcare Conference on June 8May 16, 2023 | finance.yahoo.comHere's Why SurModics (SRDX) Is a Great 'Buy the Bottom' Stock NowSee More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRDX Company Calendar Last Earnings8/02/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees447Year Founded1979Price Target and Rating Average Stock Price Forecast$59.50 High Stock Price Forecast$69.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+87.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,270,000.00 Net Margins-17.58% Pretax Margin-1.16% Return on Equity-8.34% Return on Assets-5.26% Debt Debt-to-Equity Ratio0.26 Current Ratio2.68 Quick Ratio2.22 Sales & Book Value Annual Sales$99.95 million Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.75 per share Price / Book4.09Miscellaneous Outstanding Shares14,130,000Free Float13,074,000Market Cap$447.92 million OptionableOptionable Beta1.16 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 60)CEO, Pres & Director Comp: $1.1MMr. Timothy J. Arens (Age 56)Sr. VP of Fin. & Information Technology and CFO Comp: $545.83kMr. Gordon S. Weber (Age 60)Sr. VP of Legal, Gen. Counsel & Sec. Comp: $519.6kMr. Charles W. Olson (Age 59)Sr. VP & Pres of Medical Device Coatings Comp: $523.12kMs. Teryl L. W. Sides (Age 53)Sr. VP & Pres of Vascular Interventions Comp: $613.02kMr. John D. Manders (Age 42)Corp. Controller, VP of Fin. & Principal Accounting Officer Mr. Joseph J. Stich (Age 58)Sr. VP of HR & Pres of In Vitro Diagnostics More ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXAngioDynamicsNASDAQ:ANGOAccurayNASDAQ:ARAYAlphatecNASDAQ:ATECOraSure TechnologiesNASDAQ:OSURView All CompetitorsInsiders & InstitutionsBarclays PLCSold 4,157 shares on 9/21/2023Ownership: 0.019%California State Teachers Retirement SystemSold 12,821 shares on 8/21/2023Ownership: 0.032%Nuveen Asset Management LLCBought 12,603 shares on 8/16/2023Ownership: 0.404%Gamco Investors INC. ET ALBought 400 shares on 8/15/2023Ownership: 0.544%Alliancebernstein L.P.Bought 1,520 shares on 8/15/2023Ownership: 0.115%View All Insider TransactionsView All Institutional Transactions SRDX Stock - Frequently Asked Questions Should I buy or sell Surmodics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks. What is Surmodics' stock price forecast for 2023? 2 equities research analysts have issued 12 month target prices for Surmodics' shares. Their SRDX share price forecasts range from $50.00 to $69.00. On average, they expect the company's stock price to reach $59.50 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts. How have SRDX shares performed in 2023? Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX shares have decreased by 7.1% and is now trading at $31.70. View the best growth stocks for 2023 here. When is Surmodics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our SRDX earnings forecast. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) announced its earnings results on Wednesday, August, 2nd. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.98. The company had revenue of $52.48 million for the quarter, compared to analyst estimates of $26.70 million. Surmodics had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 17.58%. What ETF holds Surmodics' stock ? Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio. What guidance has Surmodics issued on next quarter's earnings? Surmodics issued an update on its FY 2023 earnings guidance on Saturday, August, 5th. The company provided EPS guidance of -$0.29--$0.14 for the period, compared to the consensus EPS estimate of -$1.30. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $116.95 million. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX). What is Surmodics' stock symbol? Surmodics trades on the NASDAQ under the ticker symbol "SRDX." How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Surmodics' stock price today? One share of SRDX stock can currently be purchased for approximately $31.70. How much money does Surmodics make? Surmodics (NASDAQ:SRDX) has a market capitalization of $447.92 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. How many employees does Surmodics have? The company employs 447 workers across the globe. How can I contact Surmodics? Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001. This page (NASDAQ:SRDX) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.